Literature DB >> 25596110

High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma.

Lauren E Colbert1, Sarah B Fisher2, Serdar Balci3, Burcu Saka3, Zhengjia Chen4, Sungjin Kim4, Bassel F El-Rayes5, N Volkan Adsay6, Shishir K Maithel7, Jerome C Landry8, Walter J Curran9.   

Abstract

PURPOSE: To evaluate nuclear hypoxia-inducible factor 1α (HIF-1α) expression as a prognostic factor for distant recurrence (DR) and local recurrence (LR) after pancreatic adenocarcinoma resection. METHODS AND MATERIALS: Tissue specimens were collected from 98 patients with pancreatic adenocarcinoma who underwent resection without neoadjuvant therapy between January 2000 and December 2011. Local recurrence was defined as radiographic or pathologic evidence of progressive disease in the pancreas, pancreatic bed, or associated nodal regions. Distant recurrence was defined as radiographically or pathologically confirmed recurrent disease in other sites. Immunohistochemical staining was performed and scored by an independent pathologist blinded to patient outcomes. High HIF-1α overall expression score was defined as high percentage and intensity staining and thus score >1.33. Univariate analysis was performed for HIF-1α score with LR alone and with DR. Multivariate logistic regression was used to determine predictors of LR and DR.
RESULTS: Median follow-up time for all patients was 16.3 months. Eight patients (8%) demonstrated isolated LR, 26 patients (26.5%) had isolated DR, and 13 patients had both LR and DR. Fifty-three patients (54%) had high HIF-1α expression, and 45 patients (46%) had low HIF-1α expression. High HIF-1α expression was significantly associated with DR (P=.03), and low HIF-1α expression was significantly associated with isolated LR (P=.03). On multivariate logistic regression analysis, high HIF-1α was the only significant predictor of DR (odds ratio 2.46 [95% confidence interval 1.06-5.72]; P=.03). In patients with a known recurrence, an HIF-1α score ≥2.5 demonstrated a specificity of 100% for DR.
CONCLUSIONS: High HIF-1α expression is a significant predictor of distant failure versus isolated local failure in patients undergoing resection of pancreatic adenocarcinoma. Expression of HIF-1α may have utility in determining candidates for adjuvant local radiation therapy and systemic chemotherapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25596110      PMCID: PMC5746186          DOI: 10.1016/j.ijrobp.2014.11.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  34 in total

1.  Identification of clinically useful cancer prognostic factors: what are we missing?

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

2.  The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.

Authors:  David L Schwartz; Garth Powis; Arun Thitai-Kumar; Yi He; James Bankson; Ryan Williams; Robert Lemos; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Ryuichi Nishii; Mian Alauddin; Uday Mukhopadhay; Zhenghong Peng; William Bornmann; Juri Gelovani
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

Review 3.  Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Nigel B Jamieson; C Ross Carter; Colin J McKay; Karin A Oien
Journal:  Clin Cancer Res       Date:  2011-03-28       Impact factor: 12.531

4.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

5.  GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.

Authors:  Olca Basturk; Rajendra Singh; Ecmel Kaygusuz; Serdar Balci; Nevra Dursun; Nil Culhaci; N Volkan Adsay
Journal:  Pancreas       Date:  2011-03       Impact factor: 3.327

6.  REporting recommendations for tumor MARKer prognostic studies (REMARK).

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark
Journal:  Nat Clin Pract Oncol       Date:  2005-08

7.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer.

Authors:  P Birner; M Schindl; A Obermair; C Plank; G Breitenecker; G Oberhuber
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

8.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

9.  Effects of the silencing of hypoxia-inducible Factor-1 alpha on metastasis of pancreatic cancer.

Authors:  H Wei; F Li; P Fu; X Liu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2013-02       Impact factor: 3.507

10.  REporting recommendations for tumour MARKer prognostic studies (REMARK).

Authors:  L M McShane; D G Altman; W Sauerbrei; S E Taube; M Gion; G M Clark
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

View more
  14 in total

Review 1.  Targeting hypoxic response for cancer therapy.

Authors:  Elisa Paolicchi; Federica Gemignani; Marija Krstic-Demonacos; Shoukat Dedhar; Luciano Mutti; Stefano Landi
Journal:  Oncotarget       Date:  2016-03-22

2.  Distal pancreatectomy with celiac axis resection: what are the added risks?

Authors:  Joal D Beane; Michael G House; Susan C Pitt; E Molly Kilbane; Bruce L Hall; Abishek D Parmar; Taylor S Riall; Henry A Pitt
Journal:  HPB (Oxford)       Date:  2015-07-22       Impact factor: 3.647

3.  Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer.

Authors:  Tara N Fujimoto; Lauren E Colbert; Yanqing Huang; Jessica M Molkentine; Amit Deorukhkar; Laura Baseler; Meifang Yu; Daniel Lin; Sonal Gupta; Peter K Cabeceiras; Charles V Kingsley; Ramesh C Tailor; Gabriel O Sawakuchi; Eugene J Koay; Helen Piwnica-Worms; Anirban Maitra; Cullen M Taniguchi
Journal:  Cancer Res       Date:  2019-05-01       Impact factor: 12.701

4.  Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.

Authors:  Carolina J Garcia Garcia; Yanqing Huang; Natividad R Fuentes; Madeleine C Turner; Maria E Monberg; Daniel Lin; Nicholas D Nguyen; Tara N Fujimoto; Jun Zhao; Jaewon J Lee; Vincent Bernard; Meifang Yu; Abagail M Delahoussaye; Iancarlos Jimenez Sacarello; Emily G Caggiano; Jae L Phan; Amit Deorukhkar; Jessica M Molkentine; Dieter Saur; Anirban Maitra; Cullen M Taniguchi
Journal:  Gastroenterology       Date:  2022-02-22       Impact factor: 33.883

5.  Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.

Authors:  Angela Diana; Lai Mun Wang; Zenobia D'Costa; Abul Azad; Michael A Silva; Zahir Soonawalla; Paul Allen; Stanley Liu; W Gillies McKenna; Ruth J Muschel; Emmanouil Fokas
Journal:  Oncotarget       Date:  2016-11-08

6.  Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma.

Authors:  Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Seppo Parkkila; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen
Journal:  World J Surg Oncol       Date:  2018-07-04       Impact factor: 2.754

7.  A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.

Authors:  Akihisa Kato; Serina Ng; Amalraj Thangasamy; Haiyong Han; Wendi Zhou; Stephane Raeppel; Michael Fallon; Sushovan Guha; Sudhakar Ammanamanchi
Journal:  Mol Carcinog       Date:  2021-08-04       Impact factor: 5.139

8.  A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3.

Authors:  David B Shultz; Jonathan Pai; Wayland Chiu; Kendall Ng; Madeline G Hellendag; Gregory Heestand; Daniel T Chang; Dongsheng Tu; Malcolm J Moore; Wendy R Parulekar; Albert C Koong
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

9.  In vivo functional dissection of a context-dependent role for Hif1α in pancreatic tumorigenesis.

Authors:  T Cheng; Z Jian; K Li; S Raulefs; I Regel; S Shen; X Zou; J Ruland; G O Ceyhan; H Friess; C W Michalski; J Kleeff; B Kong
Journal:  Oncogenesis       Date:  2016-12-12       Impact factor: 7.485

10.  Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC.

Authors:  Lauren E Colbert; Shalini Moningi; Awalpreet Chadha; Ahmed Amer; Yeonju Lee; Robert A Wolff; Gauri Varadhachary; Jason Fleming; Matthew Katz; Prajnan Das; Sunil Krishnan; Eugene J Koay; Peter Park; Christopher H Crane; Cullen M Taniguchi
Journal:  Adv Radiat Oncol       Date:  2017-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.